CBD Oils Found to Contain Hazardous Contaminants Including Phthalates and Mycotoxins

Effect-directed screening of 13 CBD oils across 13 biological/toxicological endpoints revealed hazardous compounds including various cannabinoids with unexpected bioactivity, estrogenic contaminants (dibutyl phthalate, diisobutyl phthalate), and the estrogenic and mutagenic mycotoxin zearalenone and its metabolites.

High-performance thin-layer chromatography coupled with 13 different duplex and multiplex planar bioassays testing antimicrobial, estrogenic, androgenic, cytotoxic, neurotoxic, genotoxic, and mutagenic endpoints, with hazardous zones identified by high-resolution mass spectrometry and confirmed with reference standards.

Consumers assume CBD oils contain only CBD, but this first-of-its-kind comprehensive toxicological screening reveals a concerning array of hazardous contaminants that current quality testing may not detect.

As the CBD market grows with minimal regulation, this study demonstrates that standard potency and purity tests miss potentially dangerous contaminants that a comprehensive bioassay approach can catch.

13 products is a limited sample; bioassay detection doesn't quantify exposure risk; in vitro effects may not translate to in vivo harm at typical doses; products may not represent all markets; oxidized acylglycerides only tentatively assigned.